[Resistance to acenocoumarol revealing a missense mutation of the vitamin K epoxyde reductase VKORC1: a case report].

Abstract

A significant proportion of the interindividual variability of the response to vitamin K antagonist (VKA) treatment has been associated with genetic factors. Genetic variations affecting the vitamin K epoxide reductase complex subunit 1 (VKORC1) are associated with hypersensitivity or rarely with resistance to VKA. We report the case of a black women patient who presents a resistance to acenocoumarol. Despite the use of high doses of acenocoumarol (114 mg/week) for the treatment of recurrent pulmonary embolism, the International Normalized Ratio was below the therapeutic target. This resistance to acenocoumarol was confirmed by the identification of a missense mutation Val66Met of the vitamin K epoxide reductase.

• Authors: M C Mboup, K Dia, D M Ba, P D Fall
• Journal: Annales de cardiologie et d'angeiologie (Ann Cardiol Angeiol (Paris)) Vol. 64 Issue 1 Pg. 59-61 (Feb 2015) ISSN: 1768-3181 [Electronic] France
• Vernacular Title: Résistance à l'acénocoumarol révélant une mutation faux sens Val66Met de la vitamine K époxyde réductase VKORC1 : à propos d'une observation.
• PMID: 24095214 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Chemical References

• Anticoagulants
• VKORC1 protein, human
• Vitamin K Epoxide Reductases
• Acenocoumarol

Topics

• Acenocoumarol (therapeutic use)
• Adult
• Anticoagulants (therapeutic use)
• Drug Resistance (genetics)
• Female
• Humans
• Mutation, Missense
• Pulmonary Embolism (drug therapy)
• Vitamin K Epoxide Reductases (genetics)